Genetic Engineering

• 

  Subject Areas on Research

  • A CRISPR Activation Screen Identifies a Pan-avian Influenza Virus Inhibitory Host Factor. 
  • A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. 
  • A genetically engineered thermally responsive sustained release curcumin depot to treat neuroinflammation. 
  • A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. 
  • A lentiviral vector bearing a reverse intron demonstrates superior expression of both proteins and microRNAs. 
  • A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. 
  • A synthetic biology challenge: making cells compute. 
  • A whole more than the sum of its synthetic parts. 
  • Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. 
  • Addressing biological uncertainties in engineering gene circuits. 
  • Adeno-associated virus serotypes: vector toolkit for human gene therapy. 
  • Advances in targeted genome editing. 
  • An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. 
  • An engineered liver glycogen phosphorylase with AMP allosteric activation. 
  • An evolved AAV variant enables efficient genetic engineering of murine T cells. 
  • Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. 
  • Animal production industry in the year 2000 A.D. 
  • Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. 
  • Bacterial expression vectors for calmodulin. 
  • Biology by design: reduction and synthesis of cellular components and behaviour. 
  • Biomaterial-mediated retroviral gene transfer using self-assembled monolayers. 
  • CRISPR-Cas9-Guided Genome Engineering in Caenorhabditis elegans. 
  • Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. 
  • Cellular engineering and gene therapy strategies for insulin replacement in diabetes. 
  • Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. 
  • Characterization of a genetically engineered elastin-like polypeptide for cartilaginous tissue repair. 
  • Choosing Who Will be Disabled: Genetic Intervention and the Morality of Inclusion 
  • Chromosomally located gene fusions constructed in Acinetobacter sp. ADP1 for the detection of salicylate. 
  • Combinatorial codon scrambling enables scalable gene synthesis and amplification of repetitive proteins. 
  • Combining topographical and genetic cues to promote neuronal fate specification in stem cells. 
  • Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy. 
  • Coupling spatial segregation with synthetic circuits to control bacterial survival. 
  • Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing. 
  • Cutting of M13mp7 phage DNA and excision of cloned single-stranded sequences by restriction endonucleases. 
  • Cytogenetic engineering in vivo: restoration of biologic complement activity to C5-deficient mice by intravenous inoculation of hybrid cells. 
  • Design considerations for analyzing protein translation regulation by condensates. 
  • Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors. 
  • Dissection of genetic pathways in C. elegans. 
  • Distinct Responses of Stem Cells to Telomere Uncapping-A Potential Strategy to Improve the Safety of Cell Therapy. 
  • Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. 
  • Drosophila, genetic screens, and cardiac function. 
  • Editing the epigenome: technologies for programmable transcription and epigenetic modulation. 
  • Emancipating Chlamydia: Advances in the Genetic Manipulation of a Recalcitrant Intracellular Pathogen. 
  • Enabling functional genomics with genome engineering. 
  • Engineered cell lines for insulin replacement in diabetes: current status and future prospects. 
  • Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. 
  • Engineered transcription factors for therapeutic angiogenesis. 
  • Engineering AAV receptor footprints for gene therapy. 
  • Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity. 
  • Engineering biosynthetic excitable tissues from unexcitable cells for electrophysiological and cell therapy studies. 
  • Engineering key components in a synthetic eukaryotic signal transduction pathway. 
  • Engineering life: building a fab for biology. 
  • Engineering microbial consortia: a new frontier in synthetic biology. 
  • Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression. 
  • Equal Opportunity and Genetic Intervention 
  • Erythrocyte blood group antigens: not so simple after all. 
  • Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. 
  • Evolving sensitivity. 
  • Expression of CRISPR/Cas single guide RNAs using small tRNA promoters. 
  • Folate fortification of rice by metabolic engineering. 
  • Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. 
  • Future of early detection of lung cancer: the role of mouse models. 
  • GYGD pore motifs in neighbouring potassium channel subunits interact to determine ion selectivity. 
  • Gene assembly and combinatorial libraries in S. cerevisiae via reiterative recombination. 
  • Gene therapy and genomic strategies for cardiovascular surgery: The emerging field of surgiomics. 
  • Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice. 
  • Generation of a Mouse Full-length Balancer with Versatile Cassette-shuttling Selection Strategy. 
  • Generation of phytate-free seeds in Arabidopsis through disruption of inositol polyphosphate kinases. 
  • Genetic Correction of SOD1 Mutant iPSCs Reveals ERK and JNK Activated AP1 as a Driver of Neurodegeneration in Amyotrophic Lateral Sclerosis. 
  • Genetic Engineering of Mesenchymal Stem Cells for Differential Matrix Deposition on 3D Woven Scaffolds. 
  • Genetic bioaugmentation as an effective method for in situ bioremediation: functionality of catabolic plasmids following conjugal transfers. 
  • Genetic engineering and stem cells: combinatorial approaches for cardiac cell therapy. 
  • Genetic engineering for skeletal regenerative medicine. 
  • Genetic engineering of mesenchymal stem cells and its application in human disease therapy. 
  • Genetic engineering of vein grafts resistant to atherosclerosis. 
  • Genetic engineering: Chemical control for CRISPR editing. 
  • Genetic induction of tumorigenesis in swine. 
  • Genetic manipulation of vein grafts. 
  • Genetic therapies for xenotransplantation. 
  • Genetically engineered calmodulins differentially activate target enzymes. 
  • Genetically engineered human cancer models utilizing mammalian transgene expression. 
  • Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa. 
  • Genetically engineered probiotic competition. 
  • Genetics and ethics: reaffirming the tragic vision. 
  • Genetics in population health science: strategies and opportunities 
  • Genome engineering: a new approach to gene therapy for neuromuscular disorders. 
  • Genome engineering: the next genomic revolution. 
  • Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators. 
  • Have gene knockouts caused evolutionary reversals in the mammalian first arch? 
  • Heart and lung disease in engineered mice. 
  • Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells. 
  • Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV). 
  • Impacts of organic carbon availability and recipient bacteria characteristics on the potential for TOL plasmid genetic bioaugmentation in soil slurries. 
  • Improving the odorant sensitivity of olfactory receptor-expressing yeast with accessory proteins. 
  • In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation. 
  • Integration of foreign genes into the mammalian germ line: genetic engineering enters a new era. 
  • Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. 
  • Lesch-Nyhan syndrome. Engineering mutant mice. 
  • Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis. 
  • Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. 
  • Mechanical Stability of a Small, Highly-Luminescent Engineered Protein NanoLuc. 
  • Medical study: aspiring parents, genotypes and phenotypes: the unexamined myth of the perfect baby. 
  • Metabolic engineering with recombinant adenoviruses. 
  • Methods for analyzing bovine papilloma virus-based calmodulin expression vectors. 
  • Methods to generate genetically engineered mouse models of soft tissue sarcoma. 
  • MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. 
  • Minimal PAM specificity of a highly similar SpCas9 ortholog. 
  • Mitochondrial phosphatase PTPMT1 is essential for cardiolipin biosynthesis. 
  • Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. 
  • Molecular therapies for vascular diseases. 
  • Monoclonal antibodies for brain tumour treatment. 
  • Most of the yeast genomic sequences are not essential for cell growth and division. 
  • New lessons in the regulation of glucose metabolism taught by the glucose 6-phosphatase system. 
  • Novel insulinoma cell lines produced by iterative engineering of GLUT2, glucokinase, and human insulin expression. 
  • Oncolytic viruses for cancer therapy II. Cell-internal factors for conditional growth in neoplastic cells. 
  • Optical Control of CRISPR/Cas9 Gene Editing. 
  • Persistence and reversal of plasmid-mediated antibiotic resistance. 
  • Physiological assessment of complex cardiac phenotypes in genetically engineered mice. 
  • Prenatal gene tranfer: scientific, medical, and ethical issues: a report of the Recombinant DNA Advisory Committee. 
  • Programmable ligand detection system in plants through a synthetic signal transduction pathway. 
  • Programmable mutually exclusive alternative splicing for generating RNA and protein diversity. 
  • Programmed Allee effect in bacteria causes a tradeoff between population spread and survival. 
  • Programmed evolution for optimization of orthogonal metabolic output in bacteria. 
  • Programming stress-induced altruistic death in engineered bacteria. 
  • Prospects for cellular immunotherapy for metastatic melanoma. 
  • Rationally Designed Influenza Virus Vaccines That Are Antigenically Stable during Growth in Eggs. 
  • Recent advances in genome editing and creation of genetically modified pigs. 
  • Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. 
  • Reengineered AAV vectors: old dog, new tricks. 
  • Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. 
  • Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. 
  • Repurposing an endogenous degradation system for rapid and targeted depletion of C. elegans proteins. 
  • Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. 
  • Responsible Use of Human Gene-Editing Technologies. 
  • Retinoic acid-mediated gene expression in transgenic reporter zebrafish. 
  • Revising messages traveling along the cellular information superhighway. 
  • Riboswitches--to kill or save the messenger. 
  • Science fact and the SENS agenda. What can we reasonably expect from ageing research? 
  • Site-directed mutagenesis in the effector site of Escherichia coli phosphofructokinase. 
  • Spatial profiles of electrical mismatch determine vulnerability to conduction failure across a host-donor cell interface. 
  • Spatiotemporal modulation of biodiversity in a synthetic chemical-mediated ecosystem. 
  • Structured Illumination Microscopy and a Quantitative Image Analysis for the Detection of Positive Margins in a Pre-Clinical Genetically Engineered Mouse Model of Sarcoma. 
  • Synergistic and tunable human gene activation by combinations of synthetic transcription factors. 
  • Synthetic Biology: Reports from CSHA 2016 and More. 
  • System for expression of microsporidian methionine amino peptidase type 2 (MetAP2) in the yeast Saccharomyces cerevisiae. 
  • Systemic gene transfer to skeletal muscle using reengineered AAV vectors. 
  • Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells. 
  • Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells. 
  • The Development and Use of Reporter Influenza B Viruses. 
  • The Future of Skull Base Surgery: A View Through Tinted Glasses. 
  • The desirable donor pig to eliminate all xenoreactive antigens. 
  • The generation and characterization of novel Col1a1FRT-Cre-ER-T2-FRT and Col1a1FRT-STOP-FRT-Cre-ER-T2 mice for sequential mutagenesis. 
  • The presence of parvalbumin in a nonmuscle cell line attenuates progression through mitosis. 
  • Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. 
  • Transcription factor NF-kappaB regulates inducible CD83 gene expression in activated T lymphocytes. 
  • Transcriptional brakes on the road to adipocyte thermogenesis. 
  • Transgenic mice expressing the myotilin T57I mutation unite the pathology associated with LGMD1A and MFM. 
  • Use of genetically modified mouse models for evaluation of carcinogenic risk: considerations for the laboratory animal scientist. 
  • Using genetically engineered mice for radiation research. 
  • Using noisy gene expression mediated by engineered adenovirus to probe signaling dynamics in mammalian cells. 
  • Versatile biomanufacturing through stimulus-responsive cell-material feedback. 
  • Viral sequences enable efficient and tissue-specific expression of transgenes in Xenopus. 
  • White paper on microbial anti-cancer therapy and prevention. 
  • Windows into development: historic, current, and future perspectives on transgenic zebrafish. 
  • ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. 
  • [Insulin producing cells as therapy in diabetes mellitus]. 
  • eNOS-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation in vitro. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Hartemink, Alexander J., Professor in the Department of Computer Science, Biology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Sexton, Steven E., Mark and Lynne Florian Associate Professor of Public Policy, Economics